Kåre Schultz has announced a sweeping restructuring programme for Teva Pharmaceutical Industries Ltd that will see its workforce reduced by more than 25% and substantial changes to the company’s generic portfolio in the US. ---Subscribe to MedNous to access this article--- Company News
